Futibatinib
As of the edition of 20 October 2026, Futibatinib is a small molecule: marketed, first approved in 2022 (US); acts on FGFR1, FGFR2 and FGFR3 and 1 more; US protection ends in 2036.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Small molecule
- Brand name
- Lytgobi
- First approved
- 30 September 2022 (US)
- Approvals on record
- 5 in 3 regions
- Holder of the most recent approval
- Taiho; 3 holders in all
- Registered trials
- 25, 7 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Skin and connective tissue; Pregnancy and women's health; Urinary and reproductive
US protection
US protection ends in 2036.
The last listed US drug-substance patent ends in 2036. The application that gives this date is held by Taiho.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product8 listings count towards this date. The exact date and each listing are in the product.
See the exact date and the 8 listings behind itRequest access. Nothing is shown until you do.
Companies that need a new molecule because of this drug
4 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product4 company-target rows are on route B because of Futibatinib.
See the 4 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 4 | 0 | 2 | 2 |
| Phase 2 | 14 | 2 | 8 | 4 |
| Phase 3 | 6 | 1 | 4 | 1 |
| All trials | 25 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Taiho | Originator, Applicant and Lead sponsor of trials | 2021 to now |